(1). At a time when coronary stenting is experiencing an exponential increase, these results would appear rather provocative. Some classical studies, however, also suggested that most dissections are not only benign but also predict a lower restenosis rate (2, 3) . Nevertheless, no previous study was able to demonstrate such a low restenosis rate in this cohort of patients. Furthermore, to demonstrate convincingly that a conservative approach-namely a "watchful waiting" strategy-may even be superior in the long run to coronary stenting is much more challenging. Given the potential clinical implications of this study, some methodological clarifications appear warranted.
First, it is not clear why two patients with vessel closure were excluded. Keeping in mind that this is a retrospective study, it will be important to know whether these dissections were flow-limiting immediately after PTCA or flow deterioration occurred later on. Second, 67% (33/49) of the nontreated dissections were type A versus none (0/60) of the stented dissections (chi-square p Ͻ 0.0001). Therefore, it is difficult to assume that these two populations were similar, and thus direct comparison of results may not be appropriate. Further details on whether the restenosis rate tended to cluster around patients with type C-D dissections (untreated/stented groups) will be helpful.
Finally, the methodology of quantitative coronary analysis was not specified. This is relevant because the analysis of dissected coronary segments is technically demanding. In fact, at first glance it appears difficult to explain a mean lumen diameter post-PTCA of 3.23 Ϯ 0.65 mm (reference 3.20 Ϯ 0.54 mm) yielding a 20 Ϯ 7% diameter stenosis. The large lumen diameter of the dissected segments indicates that the dissection image was fully included into the lumen measurements. This is in contradistinction with some prior studies using careful edge-detection quantitative angiography (4, 5) . We previously demonstrated (5) that residual coronary dissections after stenting had a benign outcome when they were stable, were not associated with significant lumen narrowing, and did not compromise coronary flow.
Our data (5) also concur with the current study, suggesting that most residual dissections disappear at follow-up. Moreover, these dissected coronary segments may promote a unique pattern of vessel remodeling that could explain a lower restenosis rate (1) or even a significant lumen improvement on late angiography (5) . We fully agree with the idea that conservative management of coronary dissections is attractive in selected cases (adverse anatomy, small vessels, type A-B dissections). However, we believe that only properly designed studies will be able to determine whether this strategy is superior to stenting in most patients experiencing nonocclusive dissections. In the interim, accepting the potential risk of vessel closure and the logistic implications (prolonged observation or even repeat angiography) inherently associated with the conservative strategy should be weighted against the results of coronary stenting using currently available stent designs. Although we sympathize with the words of caution against the indiscriminate use of stents, it would appear more reasonable to challenge first the systematic use of "elective" stenting in clinical/ angiographic settings where its efficacy-as compared with PTCA-remains largely unsettled. 
REPLY
Dr. Alfonso asks why two patients in our study (1) with occlusive dissection after percutaneous transluminal coronary angioplasty (PTCA) were excluded and when these dissections occurred. As it is clearly stated in the article these two type E dissections evolved toward complete artery occlusion during the procedure and how they caused an acute myocardial infarction immediately after the procedure. Because the study reported the results of nonocclusive unstented dissections, they were excluded from the analysis at the beginning.
As far as the second point is concerned, we have acknowledged the higher prevalence of lesions A and B in the unstented group, but this limitation derives from the later stage in which the stented patients were assessed, when the easy availability of stenting allowed higher inflation pressures. However, although unstented patients had a higher prevalence of dissections grades A and B (namely 85% vs. 56% at 24 h), the restenosis rate for stented and unstented patients was similar for each dissection grade (p ϭ NS).
What we would like to stress in our study is that in this stenting era, where there is a growing and widespread use of these devices (2), the "minor" dissections (type A and B), most frequently occurring during PTCA, are associated with a very low risk of complications and restenosis, suggesting a more conservative approach.
Finally, Dr. Alfonso states that "the large lumen diameter of the dissected segments indicates that the dissection image was fully included into the lumen measurements." However, as clearly shown in Table 1 of our article, the mean lumen diameter post-PTCA in dissected vessels was not 3.23 Ϯ 0.65 mm but 3.11 Ϯ 0.89 mm, a lower value than that of the mean reference artery diameter pre-PTCA (3.18 Ϯ 0.7 mm) in the same vessels. We do agree that the methodology of quantitative coronary angiography is technically demanding, especially for the analysis of dissected segments. Therefore, we are promoting in our Institute new and different tools for quantitative analysis, such as intracoronary ultrasound (IVUS), coronary Doppler evaluation, and myocardial fractional flow-reserve measurement. Lack of effect from treatment with coenzyme Q10 in congestive heart failure is not an objective title or conclusion for the study by Watson et al. (1) in which the main limitation obviously is their sample size and its lack of study patients. Even so, the investigators state in their introduction that previous studies with coenzyme Q10 "lack credibility because of small sample sizes, lack of controls, etc."
The majority of the 27 study patients, who were not classified according to the New York Heart Association (NYHA), were seemingly at late-stage disease (mean length of symptoms 3.4 years). Mean patient age was 55 years, which is compatible with predominantly ischemic origin. This was also recently confirmed at an International Conference in Sydney, Australia-"Oxidative Pathways in Health and Disease"-in a lecture by one of the co-authors, Nicholas Bett (2). However, according to the Watson et al. (1) study, in the Patients' Demographics in Table 1 , 77% of the patients were listed as having dilated cardiomyopathy. This is a patient clientele that is, at least partially, prone to respond either spontaneously or to medical intervention with subsequent improvement of myocardial function.
Conversely, it is well-known that changes-and not least improvements-in echocardiographic parameters of left ventricular (LV) function are minimal in late-stage disease, especially in heart failure due to ischemic heart disease. This is why the
